Generic Name: pegbelfermin

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: NAFLD/NASH Medications

Company: Bristol-Myers Squibb

Approval Status: Experimental

Generic Version Available: No

Experimental Code: BMS-986036

General Info

Pegbelfermin is a fibroblast growth factor 21 analogue in Phase 2 clinical trials for treatment of non-alcoholic steatohepatitis (NASH).

Dosage

Dosing Info: N/A

Side Effects

N/A

Last Reviewed: February 4, 2019